Endevica Bio
Clinical-stage biotechnology company focused on discovery and development of engineered peptide therapeutics (peptidomimetics) for metabolic and neuroendocrine diseases. The company uses an AI-assisted peptide design platform to generate blood-brain-barrier‑permeant compounds that modulate G-protein‑coupled receptors (notably melanocortin receptors) and advances candidates through preclinical studies and Phase 1–2 clinical trials.
Industries
Nr. of Employees
small (1-50)
Endevica Bio
Patents
Products
Oral dual MC3R/MC4R agonist candidate (obesity indication)
Orally bioavailable peptide agonist designed to co-activate MC3R and MC4R to induce durable weight loss with preservation of lean mass; demonstrated efficacy and tolerability in nonhuman primate studies and evaluated for first‑in‑human testing.
MC3R/MC4R antagonist peptide candidate for cachexia
Peptide antagonist engineered to cross the blood–brain barrier to prevent or treat cachexia by modulating central melanocortin signaling; advanced from preclinical studies to Phase 1 and into Phase 2 clinical trials in cancer patients.
MC4R‑selective peptide agonist (preclinical obesity portfolio)
Preclinical MC4R-targeted peptide demonstrating weight-loss activity in diet‑induced obesity rodent studies and potential for combination therapy with GLP‑1 agents.
TCMCB07
A peptide drug developed by Endevica Bio to treat cachexia, showing promising results in a Phase 1 study.
TCMCB07 (B07)
An experimental melanocortin‐3/4 antagonist peptide drug candidate in clinical development for the treatment of cachexia, designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness.
mifomelatide
A dual MC3R/MC4R antagonist in Phase 2 clinical development to prevent and treat cachexia in patients with advanced cancer, improving appetite, stabilizing body weight, and preserving muscle and fat mass.
Oral dual MC3R/MC4R agonist candidate (obesity indication)
Orally bioavailable peptide agonist designed to co-activate MC3R and MC4R to induce durable weight loss with preservation of lean mass; demonstrated efficacy and tolerability in nonhuman primate studies and evaluated for first‑in‑human testing.
MC3R/MC4R antagonist peptide candidate for cachexia
Peptide antagonist engineered to cross the blood–brain barrier to prevent or treat cachexia by modulating central melanocortin signaling; advanced from preclinical studies to Phase 1 and into Phase 2 clinical trials in cancer patients.
MC4R‑selective peptide agonist (preclinical obesity portfolio)
Preclinical MC4R-targeted peptide demonstrating weight-loss activity in diet‑induced obesity rodent studies and potential for combination therapy with GLP‑1 agents.
TCMCB07
A peptide drug developed by Endevica Bio to treat cachexia, showing promising results in a Phase 1 study.
TCMCB07 (B07)
An experimental melanocortin‐3/4 antagonist peptide drug candidate in clinical development for the treatment of cachexia, designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness.
mifomelatide
A dual MC3R/MC4R antagonist in Phase 2 clinical development to prevent and treat cachexia in patients with advanced cancer, improving appetite, stabilizing body weight, and preserving muscle and fat mass.
Expertise Areas
- Peptide therapeutics and peptidomimetics
- GPCR/melanocortin receptor pharmacology (MC3R/MC4R)
- Preclinical translational pharmacology (rodent and NHP models)
- Oral peptide drug development
Key Technologies
- Peptide engineering / peptidomimetics
- AI-assisted molecular design
- Blood–brain barrier‑permeant peptide optimization
- GPCR pharmacology
News & Updates
Announcement of a spinout to advance a portfolio of MC3R/MC4R-targeting peptide candidates for metabolic disorders; leadership and pipeline transition described.
First patient dosing announced for a Phase 2 study of a melanocortin antagonist candidate to prevent weight loss in metastatic colorectal cancer patients; trial conducted across multiple sites with CRO partnership.
FDA authorization and initiation of a Phase 2 clinical trial to evaluate a peptide candidate for prevention of weight loss in cancer patients.
Preclinical results published demonstrating improved appetite and preservation of lean and fat mass in rodent chemotherapy models.
Preclinical research showing co-agonism of MC3R and MC4R induces significant weight loss in diet-induced obese nonhuman primates and presents an oral dual‑agonist candidate with favorable safety and rebound profile.
Multiple expert-authored articles discussing clinical importance of cachexia, economics, caregiver impact, and peptide therapeutic approaches.
Announcement of a spinout to advance a portfolio of MC3R/MC4R-targeting peptide candidates for metabolic disorders; leadership and pipeline transition described.
First patient dosing announced for a Phase 2 study of a melanocortin antagonist candidate to prevent weight loss in metastatic colorectal cancer patients; trial conducted across multiple sites with CRO partnership.
FDA authorization and initiation of a Phase 2 clinical trial to evaluate a peptide candidate for prevention of weight loss in cancer patients.
Preclinical results published demonstrating improved appetite and preservation of lean and fat mass in rodent chemotherapy models.
Preclinical research showing co-agonism of MC3R and MC4R induces significant weight loss in diet-induced obese nonhuman primates and presents an oral dual‑agonist candidate with favorable safety and rebound profile.
Multiple expert-authored articles discussing clinical importance of cachexia, economics, caregiver impact, and peptide therapeutic approaches.